12:00 AM
Jan 09, 2012
 |  BC Week In Review  |  Company News  |  Other News

Amarin cardiovascular news

In a letter to shareholders, Amarin's chairman and CEO, Joseph Zakrzewski, said it is considering three options for commercializing AMR101: partnership, acquisition and self-commercialization with third party support....

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >